SRI International Awarded $4.7 Million in Agreements to Manufacture and Test Vaccine Against Venezuelan Equine Encephalitis
April 27, 2017
April 27, 2017
MENLO PARK, Calif., April 27 -- SRI International issued the following news release:
SRI International has been awarded two agreements worth $4.7 million to manufacture and conduct clinical testing on a potential new vaccine against Venezuelan equine encephalitis (VEE), a serious viral infection for which there is currently no commercially available vaccine.
The VEE virus (VEEV) is a type of alphavirus that typically causes mild to severe influenza-like symptoms, bu . . .
SRI International has been awarded two agreements worth $4.7 million to manufacture and conduct clinical testing on a potential new vaccine against Venezuelan equine encephalitis (VEE), a serious viral infection for which there is currently no commercially available vaccine.
The VEE virus (VEEV) is a type of alphavirus that typically causes mild to severe influenza-like symptoms, bu . . .